Read this company snapshot
Daily valuation snapshot
Immunocore Holdings plc American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $29.39
- Market capitalization (USD)
- $1,513,544,353.63
- Price / earnings (TTM)
- Not reported
- Price / book
- 3.61
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research IMCR in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research IMCR in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing IMCR with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $29.39 |
| Market capitalization (USD) | $1,513,544,353.63 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.61 |
No matching rows. Clear the filter to see all records.
Read IMCR's valuation metrics
Company size
Immunocore Holdings plc American Depositary Shares's recorded market capitalization is $1,513,544,353.63. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
IMCR's recorded price-to-book ratio is 3.61. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Immunocore Holdings plc American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about IMCR. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow IMCR's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.